InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Go back to InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.81 -0.01 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.82 | 52 Week High | $0.05 | |||
| Open | $1.85 | 52 Week Low | $0.00 | |||
| Day High | $1.89 | P/E | N/A | |||
| Day Low | $1.75 | EPS | $0.00 | |||
| Volume | 1,494,163 | |||||
| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.81 -0.01 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.82 | 52 Week High | $0.05 | |||
| Open | $1.85 | 52 Week Low | $0.00 | |||
| Day High | $1.89 | P/E | N/A | |||
| Day Low | $1.75 | EPS | $0.00 | |||
| Volume | 1,494,163 | |||||
